Related references
Note: Only part of the references are listed.Acceptance and adherence to chemoprevention among women at increased risk of breast cancer
Richard G. Roetzheim et al.
BREAST (2015)
Contributors to nonadherence and nonpersistence with endocrine therapy in breast cancer survivors recruited from an online research registry
Annette L. Stanton et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Cigarette Smoking, Physical Activity, and Alcohol Consumption as Predictors of Cancer Incidence among Women at High Risk of Breast Cancer in the NSABP P-1 Trial
Stephanie R. Land et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2014)
Adherence to Endocrine Therapy in Breast Cancer Adjuvant and Prevention Settings
Rowan T. Chlebowski et al.
CANCER PREVENTION RESEARCH (2014)
Psychosocial factors in adjuvant hormone therapy for breast cancer: an emerging context for adherence research
Julia R. Van Liew et al.
JOURNAL OF CANCER SURVIVORSHIP (2014)
Use of Pharmacologic Interventions for Breast Cancer Risk Reduction: American Society of Clinical Oncology Clinical Practice Guideline
Kala Visvanathan et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Cigarette Smoking, Obesity, Physical Activity, and Alcohol Use As Predictors of Chemoprevention Adherence in the National Surgical Adjuvant Breast and Bowel Project P-1 Breast Cancer Prevention Trial
Stephanie R. Land et al.
CANCER PREVENTION RESEARCH (2011)
Predicting Adherence to Tamoxifen for Breast Cancer Adjuvant Therapy and Prevention
Jennifer H. Lin et al.
CANCER PREVENTION RESEARCH (2011)
Benefit/Risk Assessment for Breast Cancer Chemoprevention With Raloxifene or Tamoxifen for Women Age 50 Years or Older
Andrew N. Freedman et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Exemestane for Breast-Cancer Prevention in Postmenopausal Women
Paul E. Goss et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Prevalence of Tamoxifen Use for Breast Cancer Chemoprevention Among US Women
Erika A. Waters et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2010)
Symptom measurement in the Breast Cancer Prevention Trial (BCPT) (P-1): psychometric properties of a new measure of symptoms for midlife women
David Cella et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Patient centered experiences in breast cancer - Predicting long-term adherence to tamoxifen use
Katherine L. Kahn et al.
MEDICAL CARE (2007)
Adherence to drug treatment in association with how the patient perceives care and information on drugs
Johanna Ulfvarson et al.
JOURNAL OF CLINICAL NURSING (2007)
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes - The NSABP study of tamoxifen and raloxifene (STAR) P-2 trial
Victor G. Vogel et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Facts and fiction of poor compliance as a cause of inadequate blood pressure control: a systematic review
GEC Wetzels et al.
JOURNAL OF HYPERTENSION (2004)
Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention
AN Freedman et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Share Paper
